Gara Jalqabaatti › Aansa Saffoo Plasma
Qorannoo klinikaalii Aansa Saffoo Plasma Ameerikaa Keessatti hirmaatuu
Qorannoo 24 Aansa Saffoo Plasma f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Boston, MAQorannoo 5
- Houston, TXQorannoo 5
- New York City, NYQorannoo 4
- Atlanta, GAQorannoo 4
- Durham, NCQorannoo 3
- Miami, FLQorannoo 3
Naannoon
- CaliforniaQorannoo 3
- FloridaQorannoo 4
- GeorgiaQorannoo 4
- MassachusettsQorannoo 5
- New JerseyQorannoo 4
- New YorkQorannoo 6
- North CarolinaQorannoo 4
- TexasQorannoo 7
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06066359Rutgers University Study of the Genetics of Blood Cancers
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 110 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07714044Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04879043Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 7 hanga 80 · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT00106925MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT06152575A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT05651932Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT07426484Delayed Toxicities Post-CAR-T
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT07665307Pre-malignant States to Hematologic Malignancies in Firefighters
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 hanga 49 · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT06870760Registry of Older Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 65 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT01137825A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Wax-2026 · NCT05055063High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 04-Wax-2026 · NCT06313502A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Cam-2026 · NCT07052916Pilot Imaging Study of Leukemia
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 4 hanga 80 · Saalaa hunda · Haaromfame 23-Elb-2026 · NCT03633955Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Elb-2026 · NCT05336383Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Gur-2026 · NCT05745285Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Namoota walitti qabaa jira
Umuriin 21 fi ol · Saalaa hunda · Haaromfame 05-Gur-2026 · NCT07390071Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Mud-2025 · NCT06518551Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Mud-2025 · NCT06947083Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Onk-2025 · NCT07075510Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 27-Onk-2025 · NCT01137643HEME Home Transfusion Program
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2025 · NCT06487247Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Gur-2025 · NCT05597345A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 02-Hag-2024 · NCT06271252Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.